As inhibitors to WEE1, ATR and CHK1 are already in clinical trials (www.clinicaltrials.gov), we anticipate that our findings described here will provide important mechanistic insights into the targeting of cancers exhibiting replication stress. The gene discussed is ATR; the disease is cancer.